AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

赛诺菲此次出手的DR-0201，是一款 潜在同类首创靶向CD20的双抗 ，可作用于特定的组织驻留和运输髓系细胞，通过靶向吞噬作用诱导深度B细胞耗竭， 可用于治疗肿瘤和自免疾病， ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

早在2009年，华兴资本就已正式组建并购团队，为中国及全球的创新经济企业提供全面深度的并购顾问服务。在当前不确定的市场新常态下，旺盛的并购需求不断涌现，华兴资本始终陪伴创新经济企业，连接海内外，寻找新机遇。

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...

French drugmaker Sanofi has agreed to buy autoimmune disease therapy DR-0201 developed by Serbian-founded, US-based biotechnology firm Dren Bio, the two compani ...

赛诺菲大手一挥，在最新的免疫学领域投资行动中，于周四宣布了一个令人咋舌的消息：它同意掏出 6 亿美元的预付款，去收购 Dren Bio 家的在研双特异性抗体 DR-0201。这架势，就好像在说：“这个潜力股，我赛诺菲买定了！” ...

Sanofi to pay $600 million upfront payment to buy Dren Bio's bispecific myeloid cell engager, DR-0201: Paris Friday, March 21, 2025, 09:00 Hrs [IST] Sanofi and Dren Bio, Inc., a p ...

Sanofi SA is getting deeper into oncology and immunology therapy development through buying Dren Bio Inc.’s myeloid cell engager for deep B-cell depletion, DR-0201. The deal could reach as high as $1.

DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...